NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 45,481 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the sale, the insider owned 53,500 shares of the company’s stock, valued at approximately $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS opened at $36.01 on Wednesday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company has a 50 day moving average price of $34.02 and a 200 day moving average price of $32.85. The stock has a market capitalization of $4.08 billion, a P/E ratio of -20.81 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. Research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Wall Street Zen lowered shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday. Needham & Company LLC lifted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada increased their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $47.00.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC raised its holdings in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares in the last quarter. Wells Fargo & Company MN grew its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Mather Group LLC. purchased a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at $30,000. Finally, Navalign LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $46,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.